Show results for
Refine by
Immune Cells Equipment Supplied In France
8 equipment items found
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
OSE-230 is an agonist antibody against ChemR23, also known as chemerin chemokine-like receptor 1 (CMKLR1), a G-protein coupled receptor (GPCR) expressed on myeloid immune cells known to modulate inflammation. Persistent inflammation is a characteristic feature of all chronic inflammatory or autoimmune diseases and if not controlled or resolved, it can lead to ...
Manufactured by:Mega Biopharma based inCrosne, FRANCE
The empirical results yielded and critical clinical cases handled by the Doctors Camprasse over the past 25 years encourage us to consider the development of dermatologicalproducts.With the support of experts (dermatologists, aesthetic doctors, etc.), we’re thinking about the scope of possibilities – topical treatments based on Bionacre® – in skin repair and regeneration in ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
A novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets being developed by the Company to fight primary and secondary resistance mechanisms developed by cancers to evade checkpoint inhibitor ...
by:Abivax based inParis, FRANCE
ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies cells with immune enhancing potential in cancer ...
Manufactured by:Metafora Biosystems based inParis, FRANCE
METAglut1 is an in Vitro Diagnostic Medical Device used to aid in the diagnosis of the GLUT1 Deficiency Syndrome (GLUT1DS). It is a regulated health product that bears the CE mark. The first test for the daily practice developed from the METAdiag platform. ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
CoVepiT, a multi-target and multi-variant vaccine candidate against COVID-19. CoVepiT is a next-generation multi-target, multi-variant vaccine against SARS-CoV-2 in clinical Phase 1. The vaccine candidate was designed using optimized epitopes selected after screening more than 67,000 global SARS-CoV-2 genomes, as well as those of previous human-infective CoVs, SARS and MERS, to identify vaccine ...
by:Oncodesign based inDijon, FRANCE
This is the best tool you can use to evaluate new therapeutic approaches in conditions that are as close as possible to a clinical situation: ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
TG4001 is an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 ...